A Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IBI3002 in Healthy Participants and Participants With Mild to Moderate Asthma
Latest Information Update: 25 Nov 2025
At a glance
- Drugs IBI 3002 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors Innovent Biologics
Most Recent Events
- 21 Nov 2025 Status changed from recruiting to completed.
- 29 Feb 2024 According to an Innovent media release, the first participant has been dosed
- 29 Feb 2024 Status changed from not yet recruiting to recruiting, according to an Innovent media release